Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor-Reference-Cited by-同舟云学术

Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor

Published:2020-09-22 Issue:21 Volume:9 Page:8258-8265
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Zheng Guoqiao¹²^ORCID,Sundquist Kristina²³⁴,Sundquist Jan²³⁴,Försti Asta¹²⁵⁶,Hemminki Akseli⁷⁸^ORCID,Hemminki Kari¹²⁹¹⁰^ORCID

Affiliation:

1. Division of Molecular Genetic EpidemiologyGerman Cancer Research Center (DKFZ) Heidelberg Germany

2. Center for Primary Health Care Research Lund University Malmö Sweden

3. Department of Family Medicine and Community HealthDepartment of Population Health Science and PolicyIcahn School of Medicine at Mount Sinai New York NY USA

4. Center for Community‐based Healthcare Research and Education (CoHRE) Department of Functional Pathology School of Medicine Shimane University Shimane Japan

5. Hopp Children's Cancer Center (KiTZ) Heidelberg Germany

6. Division of Pediatric Neurooncology German Cancer Research Center (DKFZ) German Cancer Consortium (DKTK) Heidelberg Germany

7. Cancer Gene Therapy Group Translational Immunology Research Program University of Helsinki Helsinki Finland

8. Comprehensive Cancer Center Helsinki University Hospital Helsinki Finland

9. Division of Cancer EpidemiologyGerman Cancer Research Center (DKFZ) Heidelberg Germany

10. Faculty of Medicine and Biomedical Center in Pilsen Charles University in Prague Pilsen Czech Republic

Funder

Novo Nordisk Fonden

China Scholarship Council

Jane ja Aatos Erkon Säätiö

Päivikki ja Sakari Sohlbergin Säätiö

Helsingin Yliopisto

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3454

Reference36 articles.

1. MULTIPLE MALIGNANT NEOPLASMS

2. Prostate cancer survivors: Risk and mortality in second primary cancers

3. Familial risks and mortality in second primary cancers in melanoma;Chattopadhyay S;JNCI Cancer Spectrum,2019

4. Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives

5. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How Can Spatial Transcriptomic Profiling Advance Our Understanding of Skin Diseases?;Journal of Investigative Dermatology;2024-08

2. Subsequent malignant neoplasms after primary hematological malignancy in adult patients;International Journal of Cancer;2024-04-25

3. Risk of second primary cancers after a diagnosis of first primary cancer: A pan-cancer analysis and Mendelian randomization study;eLife;2023-11-02

4. Risk of Second Primary Cancers After a Diagnosis of First Primary Cancer: A Pan-Cancer Analysis and Mendelian Randomization Study;2023-02-23

5. A single centre study from western India to evaluate the frequency of developing second and subsequent multiple primary malignancies among cancer survivors;Surgical and Experimental Pathology;2022-09-23